Table 5 Review of studies comparing MBC and TNBC
| Â | Outcomes (MBC vs TNBC) | |||||||
|---|---|---|---|---|---|---|---|---|
Author (year) | Sample (N) | Matching | Analysis | DFS % (p) | DFS HR (p) | OS % (p) | OS HR (p) | Chemotherapy |
Lee H, et al. (2012) [31] | MBC = 67 TNBC = 520 | 1:8 -Stage | Univariate |  | 3.65 (p < 0.001) |  | 3.5 (p < 0.001) | MBC and TNBC stage I–III: -16.7% and 20.5% anthracycline- and taxane (combination)-based NACTx MBC and TNBC recurrence or stage IV: -17% anthracycline based -35% taxane based -30% capecitabine containing -17% other Distribution of regimens between MBC and TNBC (p = 0.280) |
Multivariate | Â | 2.53 (p = 0.005) | Â | 2.56 (p = 0.017) | ||||
Aydiner A, et al. (2015) [32] | MBC = 54 TNBC = 51 | 1:1 -Clinical and pathologic features -Demographic features -Treatment modality | Univariate | PFS* 3 years 51% vs 82% (p = 0.013) |  | 3 years 68% vs 94% (p = 0.009) |  | MBC and TNBC stage I–IV: - 36% and 28% anthracycline based - 2% and 8% taxane based - 48% and 64% anthracycline + taxane based - 14% and 0% other regimens Distribution of regimens between MBC and TNBC (p = 0.67) |
Multivariate | Â | PFS* 0.09 (p < 0.001) | Â | 0.35 (p = 0.19) | ||||
El Zein D, et al. (2017) [33] | MBC = 46 TNBC = 508 | 1:1 -Age -Stage -Grade -Treatment setting -Treatment modality | Univariate | 5 years 74% vs 90% (p < 0.001) |  | 5 years 65% vs 87% (p = 0.002) |  | MBC stage I–III: -78.6% AC/T -4.3% CMF -2.1% MAID -6.5% carboplatin based -4.3% gemcitabine based Distribution of regimens between MBC and TNBC (p = N/A) |
Multivariate | Â | 1.99 (p = 0.05) | Â | 1.50 (p = 0.25) | ||||
Song Y, et al. (2013) [34] | MBC = 55 TNBC = 131 | 1:2 -Age -Period of diagnosis | Univariate | 5 years 46% vs 60% (p < 0.001) |  | 5 years 55% vs 73% (p < 0.001) |  | MBC stage I–III: -37.5% TAC adjuvant CTx -14.5% CMF adjuvant CTx -14.5% FAC adjuvant CTx -18.75% FAC→TC adjuvant CTx -8.3% TAC + cisplatin/capecitabine adjuvant CTx -6.25% TAC + capecitabine/vinorelbine adjuvant CTx Distribution of regimens betweenMBC and TNBC (p = N/A) |
Multivariate | Not performed vs TN-IDC | Â | Not performed vs TN-IDC | Â | ||||
Current study | MBC = 44 TNBC = 130 | 1:3 -Age -Stage | Univariate | DDFS* 5 years 78% vs 79% (p = 0.35) |  | 5 years 79% vs 81% (p = 0.32) |  | MBC and TNBC stage I–IV: -70.5% and 77.7% AC -4.5% and 6.9% TC -2.3% and 0.8% FEC -0.0% and 0.8% docetaxel + carboplatin -13.6% and 11.5% paclitaxel + carboplatin -0.0% and 0.8% gemcitabine + cisplatin -0.0% and 1.5% gemcitabine + paclitaxel No significant differences in regimen use between MBC and TNBC. MBC and TNBC stage I–IV: -77.3% and 80.0% anthracycline received -13.6% and 13.1% platinum received -70.5% and 85.4% taxane received Significant difference in taxane use between groups (p = 0.041) |
Multivariate | Â | DDFS* 1.64 (p = 0.22) | Â | 1.64 (p = 0.26) | ||||